3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Conditions
Uterine Cervical Neoplasms
3
Urinary Bladder Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Prostatic Neoplasms
3
Ovarian Neoplasms
3
Esophageal Neoplasms
3
Endometrial Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Pancreatic Neoplasms
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Interventions
pembrolizumab
29
Cetuximab
11
Nivolumab
10
Fluorouracil
8
Cyclophosphamide
8
Cisplatin
8
Carboplatin
8
fludarabine
7
atezolizumab
7
Blood Specimen Collection
7
cemiplimab
6
Radiotherapy
6
Drug Therapy
6
Immune Checkpoint Inhibitors
5
Gemcitabine
5
Paclitaxel
4
Docetaxel
4
Capecitabine
4
Biopsy
4
spartalizumab
3
avelumab
3
Surveys and Questionnaires
3
Pemetrexed
3
Oncolytic Virotherapy
3
Nicotine
3
Magnetic Resonance Spectroscopy
3
Irinotecan
3
Ipilimumab
3
Interleukin-2
3
Bortezomib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Head and Neck Neoplasms
×
tisotumab vedotin
×
Gastrointestinal
×
Clear all
NCT03485209
2026-04-20
innovaTV 207
Seagen Inc.
Phase 2
Active not recruiting
350 enrolled